clinical evaluation of Panchtikta Churna in Madhumeha (type 2 Diabetes Mellitus)

Evaluation of Hypoglycemic activity (invitro) and clinical efficacy of Panchtikta Churna in Madhumeha (type 2 Diabetes Mellitus): A Preliminary Study - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/01/061587

Enrollment

Registered

2024-01-18

Start date

Unknown

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications Health Condition 2: E119- Type 2 diabetes mellitus without complications Health Condition 3: E119- Type 2 diabetes mellitus without complications Health Condition 4: E119- Type 2 diabetes mellitus without complications Health Condition 5: E119- Type 2 diabetes mellitus without complications

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of age group 18 to 60 years of either sex. 2. Fasting plasma glucose = 126 mg/dl or Post Prandial glucose level = 200 mg/dl. 3. The HbA1c levels should lie within the range of > 6.5% to ( According to American Diabetes Association, ADA ,2022 guidelines)

Exclusion criteria

Exclusion criteria: 1. Patients having sign and symptoms of complication of Type 2 Diabetes Mellitus like Nephropathy, Retinopathy, Neuropathy. 2. Patients with gestational diabetes mellitus or pregnant women . 3. Patients suffering from any chronic diseases such as Bronchial asthma , COPD, Chronic kidney disease , Ischaemic heart diseases , Fatty liver stage 3 and Chronic illness of other body organs , uncontrolled High blood pressure (Systolic more than 160 and diastolic more than 100 mm of Hg) 4. Patients who are diagnosed with malignancy of any system. 5. Patients currently using oral hypoglycemic agents (Conventional).

Design outcomes

Primary

Measure	Time frame
Decrease in HbA1c values in patientsTimepoint: 3 months	—

Secondary

Measure	Time frame
20% decrease in Fasting blood sugar or PP blood sugar or HbA1c.Timepoint: 3 months	—

Countries

India

Contacts

Public ContactDr Shalini Varshney

A and U Tibbia college and Hospital

shalinidr.v7@gmail.com9354925050

Outcome results